News & Updates

Show Multimedia Only
Scalp cooling reduces chemo-induced alopecia in gynaecological cancers
Scalp cooling reduces chemo-induced alopecia in gynaecological cancers
04 May 2026 byKanas Chan

Scalp cooling (or scalp hypothermia) reduces chemotherapy-induced alopecia, alleviates psychological distress, and improves quality of life (QoL) in patients with primary gynaecologic cancers receiving carboplatin plus paclitaxel, the single-centre, randomized controlled CHARM trial has shown. 

Scalp cooling reduces chemo-induced alopecia in gynaecological cancers
04 May 2026
Brolucizumab a viable alternative in proliferative diabetic retinopathy
Brolucizumab a viable alternative in proliferative diabetic retinopathy
02 May 2026 byJairia Dela Cruz

In the treatment of patients with proliferative diabetic retinopathy, brolucizumab outperforms panretinal laser photocoagulation in terms of preserving visual acuity, according to the international phase III CONDOR trial.

Brolucizumab a viable alternative in proliferative diabetic retinopathy
02 May 2026
Semaglutide may avert adult-onset epilepsy in patients with diabetes
Semaglutide may avert adult-onset epilepsy in patients with diabetes
01 May 2026 byStephen Padilla

Treatment with semaglutide appears effective in reducing the risk of adult-onset epilepsy or seizures relative to sodium–glucose cotransporter-2 inhibitors (SGLT2i) and other glucose-lowering drugs (GLDs) in patients with type 2 diabetes mellitus (T2DM), according to a study presented at AAN 2026.

Semaglutide may avert adult-onset epilepsy in patients with diabetes
01 May 2026